Cargando…
Trends in Out-of-Pocket Cost of Glucagon, 2010-2020
This cross-sectional study investigates trends in out-of-pocket costs for unmixed and novel glucagon formulations among patients with Medicare Advantage and commercial insurance from 2010 to 2020.
Autores principales: | Zupa, Margaret, Feldman, Robert, Luo, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428735/ https://www.ncbi.nlm.nih.gov/pubmed/36040744 http://dx.doi.org/10.1001/jamanetworkopen.2022.29428 |
Ejemplares similares
-
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
por: Luo, Jing, et al.
Publicado: (2020) -
Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022) -
Trends in and Factors Associated With Out-of-Pocket Spending for COVID-19 Hospitalizations From March 2020 to March 2021
por: Chua, Kao-Ping, et al.
Publicado: (2022) -
Estimating the Cancer Treatment Cost for 5 Common Types of Cancer with Separating Out-of-Pocket and Governmental Costs in Afghanistan, 2020
por: Abdullah, Maihan, et al.
Publicado: (2023) -
Trends in Well-Child Visits With Out-of-Pocket Costs in the US Before and After the Affordable Care Act
por: Shafer, Paul R., et al.
Publicado: (2021)